Rallybio Corporation
RLYB
$0.626
$0.0325.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -29.10% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -29.10% | -- | -- | -- | -- |
| Cost of Revenue | -19.95% | -47.65% | -53.62% | -37.99% | -94.12% |
| Gross Profit | 14.16% | 49.59% | 53.86% | 40.24% | 96.40% |
| SG&A Expenses | -4.40% | -25.11% | -17.87% | -32.10% | -36.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.76% | -40.06% | -44.84% | -36.14% | -13.69% |
| Operating Income | 40.96% | 41.35% | 45.02% | 37.69% | 15.18% |
| Income Before Tax | 40.24% | 50.40% | 45.44% | 37.60% | 12.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.24% | 50.40% | 45.44% | 37.60% | 12.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.24% | 50.40% | 45.44% | 37.60% | 12.85% |
| EBIT | 40.96% | 41.35% | 45.02% | 37.69% | 15.18% |
| EBITDA | 41.00% | 41.39% | 45.07% | 37.73% | 15.19% |
| EPS Basic | 41.18% | 54.83% | 50.35% | 43.28% | 20.30% |
| Normalized Basic EPS | 41.22% | 45.33% | 50.34% | 43.28% | 20.28% |
| EPS Diluted | 41.18% | 54.83% | 50.35% | 43.28% | 20.30% |
| Normalized Diluted EPS | 41.22% | 45.33% | 50.34% | 43.28% | 20.28% |
| Average Basic Shares Outstanding | 1.62% | 9.81% | 9.89% | 10.02% | 9.33% |
| Average Diluted Shares Outstanding | 1.62% | 9.81% | 9.89% | 10.02% | 9.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |